Americans may be offered a single dose of a Covid vaccine each autumn, much as they are given flu shots, the Food and Drug Administration (FDA) announced on Monday. Not all FDA advisers are happy about the plans, however. The New York Times has the story.
The proposal took some scientists by surprise, including a few of the FDA’s own advisers. They are scheduled to meet on Thursday to discuss the country’s vaccine strategy, including which doses should be offered and on what schedule.
“I’m choosing to believe that they are open to advice, and that they haven’t already made up their minds as to exactly what they’re going to do,” Dr. Paul Offit, one of the advisers and director of the Vaccine Education Center at Children’s Hospital of Philadelphia, said of FDA officials.
There was little research to support the suggested plan, some advisers said.
“I’d like to see some data on the effect of dosing interval, at least observational data,” said Dr. Eric Rubin, one of the advisers and editor in chief of the New England Journal of Medicine. “And going forward, I’d like to see data collected to try to tell if we’re doing the right thing.”
Still, Dr. Rubin added, “I’d definitely be in favor of something simpler, as it would make it more likely that people might take it.”
Only about 40% of adults aged 65 and older, and only 16% of those five and older, have received the latest Covid booster shot. Many experts, including federal officials, have said that the doses are most important for Americans at high risk of severe disease and death from Covid: older adults, immunocompromised people, pregnant women and those with multiple underlying conditions.
In its briefing documents, the FDA addressed the varying risks to people of different ages and health status.
“Most individuals may only need to receive one dose of an approved or authorized Covid-19 vaccine to restore protective immunity for a period of time,” the agency said. Very young children who may not already have been infected with the virus, as well as older adults and immunocompromised people, may need two shots, the documents said.
But some scientists said there was little to suggest that Americans at low risk needed even a single annual shot. …
The FDA advisers said they would like to see detailed information regarding who is most vulnerable to the virus and to make decisions about future vaccination strategy based on those data.
“How old are they? What are their comorbidities? When was the last dose of vaccine they got? Did they take antiviral medicines?” Dr. Offit said. At the moment, the national strategy seems to be, “‘OK, well, let’s just dose everybody all the time,’” he said. “And that’s just not a good reason.”
According to the FDA’s suggested plan, officials would choose the annual vaccine’s composition each June, targeted to fight whatever variant is circulating.
But this year, the booster was quickly outpaced by newly evolved variants. It might make more sense to develop vaccines that target parts of the coronavirus other than the so-called spike protein, which changes less frequently, some researchers said.
Dr. Céline Gounder, an infectious disease physician and senior fellow at the Kaiser Family Foundation, said that the plan makes no sense as most people are “well protected against severe Covid disease with a primary series and without yearly boosters”.
“This makes no sense, based on what we’ve learned from the current bivalent vaccine and imprinting. Why not switch to a monovalent Omicron vaccine?” she added.
The FDA advisers said they hoped the meeting on Thursday would allow for robust discussion of such questions. But Dr. Gounder was sceptical. The voting questions “are framed in such a way as to force a certain outcome,” she said.
Worth reading in full.
Profanity and abuse will be removed and may lead to a permanent ban.